Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 12 Receptor (IL12R) targeted pipeline therapeutics. 

The report provides comprehensive information on the Interleukin 12 Receptor (IL12R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 12 Receptor (IL12R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 12 Receptor (IL12R) 
- The report reviews Interleukin 12 Receptor (IL12R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Interleukin 12 Receptor (IL12R) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Interleukin 12 Receptor (IL12R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Interleukin 12 Receptor (IL12R) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Interleukin 12 Receptor (IL12R) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 12 Receptor (IL12R) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Interleukin 12 Receptor (IL12R) Overview 6
Therapeutics Development 7
Interleukin 12 Receptor (IL12R) - Products under Development by Stage of Development 7
Interleukin 12 Receptor (IL12R) - Products under Development by Therapy Area 8
Interleukin 12 Receptor (IL12R) - Products under Development by Indication 9
Interleukin 12 Receptor (IL12R) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Interleukin 12 Receptor (IL12R) - Products under Development by Companies 12
Interleukin 12 Receptor (IL12R) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Interleukin 12 Receptor (IL12R) - Companies Involved in Therapeutics Development 20
Eli Lilly and Company 20
Mallinckrodt Plc 21
Merck KGaA 22
Neumedicines Inc 23
Interleukin 12 Receptor (IL12R) - Drug Profiles 24
Cellular Immunotherapy to Activate Interleukin-12 for Skin Cancer - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
edodekin alfa SR - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
LY-3232094 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
M-9241 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
NMIL-121 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Interleukin 12 Receptor (IL12R) - Dormant Projects 32
Interleukin 12 Receptor (IL12R) - Discontinued Products 33
Interleukin 12 Receptor (IL12R) - Featured News & Press Releases 34
Mar 02, 2015: Department of Defense Supports Neumedicines With Groundbreaking Grant for Surgical Site Infection Therapy 34
Apr 28, 2014: Phase I Clinical Study of Neumedicines' Interleukin-12 as a Treatment for Wound Healing and Infections Recommended for Funding by the U.S. Department of Defense 34
Apr 18, 2014: Neumedicines Publishes Clinical Data Demonstrating Safety and Hematopoietic and Immune Effects of HemaMax (rHuIL-12), a Radiation Medical Countermeasure 35
Apr 15, 2014: Neumedicines Announces Publication of Phase II-Equivalent Data Demonstrating the Survival Effect of HemaMax (rHuIL-12), a Radiation Medical Countermeasure 36
Jan 09, 2014: Neumedicines to Feature HemaMax Study Results in Presentation at Biotech Showcase Conference 36
Dec 13, 2013: Neumedicines Presents HemaMax Clinical Data at the ASH Conference 37
Jun 10, 2013: Neumedicines Receives $8.3m Award From BARDA For Continued Development Of HemaMax As Countermeasure To Acute Radiation Exposure 38
May 14, 2013: Neumedicines Receives BARDA Notification Of Intent To Exercise Contract Option To Continue Development Of HemaMax As Radiation Medical Countermeasure 38
Jan 25, 2013: Neumedicines Presents Data On HemaMax At BARDA And NIAID Sponsored Symposium 39
Jul 23, 2012: TherapyX Partners with Neumedicines 40
May 05, 2012: Neumedicines's HemaMax Demonstrates Unprecedented Survivability After Lethal Dose Of Radiation In Mice And Non-Human Primates 40
Mar 05, 2012: Neumedicines's HemaMax Demonstrates Positive Preclinical Results After Lethal Dose Of Radiation In Mice And Non-Human Primates 42
Sep 27, 2011: Neumedicines Wins US Federal Government Contract Up To $273m To Fund Late-Stage Development Of HemaMax 43
Jan 31, 2011: Neumedicines Receives Notice Of Allowance For Patent Covering Use Of HemaMax To Treat Chemotherapy-Induced Thrombocytopenia 44
Aug 12, 2010: Neumedicines Receives $2.5 Million From HHS/BARDA After Successful Non-Human Primate Studies to Further Advance HemaMax As a Radiation Countermeasure 44

Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 19
Pipeline by Eli Lilly and Company, H2 2016 20
Pipeline by Mallinckrodt Plc, H2 2016 21
Pipeline by Merck KGaA, H2 2016 22
Pipeline by Neumedicines Inc, H2 2016 23
Dormant Projects, H2 2016 32
Discontinued Products, H2 2016 33